Advanced non-small cell lung cancer therapy: Historical and future perspectives

Targeted Oncology

Volumn 3, Issue 3, 2008, Pages 135-147

  Reck, M ^a   Gatzemeier, U ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Chemotherapy; Non small cell lung cancer (NSCLC); Radiotherapy; Survival; Targeted therapies

Indexed keywords

EID: 49749091665     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0082-9     Document Type: Review

References (89)

1. Stewart BW, Kleihues P (2003) World Cancer Report. IARC, Lyon
2. DC Ihde 1992 Chemotherapy of lung cancer N Engl J Med 327 1434 1441
3. DC Ihde JD Minna 1991 Non-small cell lung cancer: part II Treatment Curr Probl Cancer 15 109 154
4. DH Johnson 1990 Chemotherapy for unresectable non-small cell lung cancer Semin Oncol 17 20 29
5. DM Finkelstein DS Ettinger JC Ruckdeschel 1986 Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 4 702 709
6. DH Johnson 2000 Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the Eastern Cooperative Oncology Group experience Chest 117 133 137
7. B Roswit ME Patno R Rapp 1968 The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo Radiology 90 688 697
8. DH Johnson LH Einhorn A Bartolucci 1990 Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer Ann Intern Med 113 33 38
9. RO Dillman C Berry KP Ryan 1991 Recent outcomes for patients with carcinoma of the lung Cancer Invest 9 9 17
10. DG Payne 1988 Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy J Clin Oncol 6 552 558
11. P Marino A Preatoni A Cantoni 1995 Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer A meta-analysis. Cancer 76 593 601
12. RO Dillman J Herndon SL Seagren 1996 Improved survival in stage III non-small-cell lung cancer: 7-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1210 1215
13. WT Sause C Scott S Taylor 1995 Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer J Natl Cancer Inst 87 198 205
14. C Schaake-Koning BW van den O Dalesio 1992 Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer N Engl J Med 326 524 530
15. B Jeremic Y Shibamoto L Acimovic 1996 Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study J Clin Oncol 14 1065 1070
16. K Furuse M Fukuoka M Kawahara 1999 Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 2692 2699
17. P Zatloukal L Petruzelka M Zemanova 2004 Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Lung Cancer 46 87 98
18. WJ Curran CB Scott CJ Langer 2003 Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410 Proc Am Soc Clin Oncol 22 2499
19. Non-small Cell Lung Cancer Collaborative Group 1995 Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 899 909
20. EF Smit JP van Meerbeeck P Lianes 2003 Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975 J Clin Oncol 21 3909 3917
21. C Gridelli C Gallo FA Shepherd 2003 Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 3025 3034
22. R Rosell U Gatzemeier DC Betticher 2002 Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann Oncol 13 1539 1549
23. PA Bunn Jr. 2002 Treatment of advanced non-small-cell lung cancer with two-drug combinations J Clin Oncol 20 3565 3567
24. K Kelly J Crowley PA Bunn Jr. 2001 Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 3210 3218
25. GV Scagliotti MF De M Rinaldi 2002 Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 4285 4291
26. P Comella G Filippelli CG De 2007 Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101) Ann Oncol 18 324 330
27. DG Pfister DH Johnson CG Azzoli 2004 American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 330 353
28. JL Pujol F Barlesi JP Daures 2006 Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials Lung Cancer 51 335 345
29. G D'Addario M Pintilie NB Leighl 2005 Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature J Clin Oncol 23 2926 2936
30. A Paccagnella F Oniga A Bearz 2006 Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study J Clin Oncol 24 681 687
31. FV Fossella JS Lee WK Hong 1997 Management strategies for recurrent non-small cell lung cancer Semin Oncol 24 455 462
32. J Dancey FA Shepherd RJ Gralla 2004 Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial Lung Cancer 43 183 194
33. FA Shepherd J Dancey R Ramlau 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103
34. N Hanna FA Shepherd FV Fossella 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597
35. H Wakelee CP Belani 2005 Optimizing first-line treatment options for patients with advanced NSCLC Oncologist 10 Suppl. 3 1 10
36. JH Schiller D Harrington CP Belani 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98
37. AB Sandler DH Johnson RS Herbst 2004 Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer Clin Cancer Res 10 4258s 4262s
38. G Bergers LE Benjamin 2003 Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 401 410
39. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676
40. RTP Poon ST Fan J Wong 2001 Clinical implications of circulating angiogenic factors in cancer patients J Clin Oncol 19 1207 1225
41. C Arteaga 2003 Targeting HER1/EGFR: a molecular approach to cancer therapy Semin Oncol 30 3 14
42. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signaling network Nat Rev Mol Cell Biol 2 127 137
43. S Oliveira PM van Bergen en Henegouwen G Storm 2006 Molecular biology of epidermal growth factor receptor inhibition for cancer therapy Expert Opin Biol Ther 6 605 617
44. LG Presta H Chen SJ O'Connor 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599
45. BQ Shen S Stainton D Li 2004 Combination of Avastin and Xeloda synergistically inhibits colorectal tumor growth in a COLO205 tumor xenograft model Proc Am Assoc Cancer Res 45 508
46. DH Johnson L Fehrenbacher WF Novotny 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184 2191
47. A Sandler R Gray MC Perry 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550
48. National Comprehensive Cancer Network (2008) Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.2.2008. Accessed at http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
49. C Manegold J von Pawel P Zatloukal 2007 Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) European Journal of Cancer Supplements 5 357
50. C Manegold J von Pawel P Zatloukal 2007 Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 J Clin Oncol 25 June 20 Suppl. 388s
51. M Reck J von Pawel P Zatloukal 2007 BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) J Thor Oncol 2 Suppl. 4 S360
52. F Ciardiello R Bianco V Damiano 1999 Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin Cancer Res 5 909 916
53. K Kelly N Hanna P Rosenberg 2003 A multicentered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer Proc Am Soc Clin Oncol 22 644
54. F Robert GR Blumenschein K Dicke 2003 Phase IB/IIA study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 643
55. R Rosell C Daniel R Ramlau 2004 Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 618
56. JD Moyer EG Barbacci KK Iwata 1997 Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 4838 4848
57. VA Pollack DM Savage DA Baker 1999 Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 739 748
58. JD Patel VA Miller MG Kris 2003 Encouraging activity and durable responses demonstrated by the EGFR tyrosine kinase inhibitor erlotinib (Tarceva, OSI-774) in patients with advanced bronchioalveolar (BAC) cell carcinoma Lung Cancer 41 S56
59. U Gatzemeier A Pluzanska A Szczesna 2004 Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 22 July 15 Suppl. 619s
60. RS Herbst D Prager R Hermann 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892 5899
61. G Giaccone RS Herbst C Manegold 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777784
62. RS Herbst G Giaccone JH Schiller 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 785 794
63. B Liu T Barrett P Choyke 2006 A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC) J Clin Oncol 24 June 20 Suppl 17119
64. DB Mendel AD Laird X Xin 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337
65. AJ Schueneman E Himmelfarb L Geng 2003 SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models Cancer Res 63 4009 4016
66. SA Laurie A Arnold I Gauthier 2006 Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) J Clin Oncol 24 June 20 Suppl 3054
67. JV Heymach BE Johnson J Rowbottom 2005 A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC J Clin Oncol 23 June 1 Suppl 197S
68. BE Johnson P Ma H West 2005 Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC J Clin Oncol 23 June 1 Suppl 645S
69. TJ Lynch R Lilenbaum P Bonomi 2004 A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 634
70. ES Kim AM Mauer H Tran 2003 A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report Proc Am Soc Clin Oncol 22 642
71. N Thatcher A Chang P Parikh 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537
72. JY Douillard E Kim V Hirsh 2007 Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST) J Thorac Oncol 2 S305
73. S Niho Y Ichinose T Tamura 2007 Results of a randomized phase III study to compare the overall survival of gefitinib versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens J Clin Oncol 25 June 20 Suppl. 387s
74. FA Shepherd PJ Rodrigues T Ciuleanu 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132
75. A Bezjak D Tu L Seymour 2006 Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 24 3831 3837
76. OSI Pharmaceuticals (2005) Tarceva prescribing information. OSI Pharmaceuticals, Melville
77. Sanofi-Aventis (2005) Docetaxel prescribing information. Sanofi-Aventis, Paris
78. Eli Lilly (2005) Pemetrexed prescribing information. Eli Lilly, Basingstroke
79. U Gatzemeier GR Blumenschein FV Fossella 2006 Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma J Clin Oncol 24 June 20 Suppl 7002
80. JV Heymach 2005 ZD6474-clinical experience to date Br J Cancer 92 Suppl. 1 S14 20
81. RS Herbst DH Johnson E Mininberg 2005 Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2544 2555
82. RS Herbst L Fehrenbacher CP Belani 2006 A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer Eur J Cancer Suppl 4 20
83. R Rosell M Cuello F Cecere 2006 Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going Curr Opin Oncol 18 135 143
84. R Rosell F Cecere M Santarpia 2006 Predicting the outcome of chemotherapy for lung cancer Curr Opin Pharmacol 6 323 331
85. M Santarpia G Altavilla F Salazar 2006 From the bench to the bed: individualizing treatment in non-small-cell lung cancer Clin Transl Oncol 8 71 76
86. MS Tsao A Sakurada JC Cutz 2005 Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 133 144
87. MS Tsao S Kamel-Reid FA Shepherd 2006 Assessing EGFR mutations N Engl J Med 354 527 528
88. MS Gordon K Margolin M Talpaz 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843 850
89. L Crino E Dansin P Garrido Lopez 2007 First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390) European Journal of Cancer Supplements 5 386